Early hydroxychloroquine is associated with an increase of survival in COVID-19 patients: an observational study.

Publication
Title	Early Hydroxychloroquine Is Associated with an Increase of Survival in COVID-19 Patients: An Observational Study
Authors	Francisco Membrillo German Ramirez-Olivencia Miriam Estebanez ... Lucia Ballester
Journal	Preprints.org
Date	May 6, 2020

Observational study in Spain of early treatment with hydroxychloroquine in 166 COVID-19 patients showed a significant survival benefit in patients started on hydroxychloroquine in the mild stage of disease.

Patients were categorized into one of three groups at initial presentation: mild, moderate or severe. There was a significant survival benefit in the mild group compared to controls (1.8 times, p = 0.032) and a trend toward survival benefit in the moderate and severe groups (1.4 times and 1.6 times, respectively). Of note, the average time between symptom onset and treatment was 7 days.

Major Issues

No major issues identified at this time.

Minor Issues

No minor issues identified at this time.

Impact

This is another retrospective analysis that suggests efficacy of early treatment with hydroxychloroquine against COVID-19.

Article Revisions

None at this time.